2025 Q2 -tulosraportti
141 päivää sitten37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
21 217
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 250 | - | - | ||
| 2 000 | - | - | ||
| 22 524 | - | - | ||
| 2 076 | - | - |
Ylin
1,07VWAP
Alin
0,987VaihtoMäärä
2,3 2 224 688
VWAP
Ylin
1,07Alin
0,987VaihtoMäärä
2,3 2 224 688
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenNow, the lack of insider buying can no longer be used against Circio. More such announcements will come as the entire management/board invests in this emission. A clearer "message" is hard to find.
·1 t sitten · MuokattuExciting announcement!!·11 min sittenThe market is sleeping... Just stay put and let the algos run their course- ·3 t sitten · MuokattuNo one can guarantee anything in listed stocks. What one knows is that Circio has made significant progress in its technology development with several results, they underpin each other and reveal the potential of circVec. A number of collaboration projects with external parties testing the technology, a paid study from big pharma, all help to substantiate that there is substance in the technology they have developed over the last 3 years. Large amounts have been invested. Furthermore, we now know that a financial basis for further developing circVec is guaranteed. The assessment is whether this justifies an mcap of 2 -250.mill including the capital that is now coming in. What is the risk compared to the possible reward in the next 12 months? My opinion is that it will take little in terms of new good results or agreements before one will see a completely different mcap for Circio. As a shareholder, one just has to live through these 14 emission days. Circio's emission cannot be compared with most others that one has seen in recent years. I do not want to be out of this stock for the next six months.·1 t sitten · MuokattuI'm not a bio expert, but after having been in and out of various such bio stocks in recent years, it is my personal opinion that this is the biotech stock on the exchange here that has the most potential and best risk/reward. The entry price and mcap are still low, the technology has enormous potential in many treatments and areas, the risk is lower as it will not primarily run its own long-term studies with win-or-lose outcomes. The risk is spread across many areas. And now the financing is finally in place.
·5 t sittenWhat are the odds that this becomes like zenith energy, falling down to 0.4/0.5 and going up and down a few percent there for a lifetime? Need some convincing words here soon😂- ·5 t sittenWho thinks that circio can actually come with some news early next week to get as many as possible to buy shares and subscribe to the emission. 🧲
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
141 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenNow, the lack of insider buying can no longer be used against Circio. More such announcements will come as the entire management/board invests in this emission. A clearer "message" is hard to find.
- ·1 t sitten · MuokattuExciting announcement!!·11 min sittenThe market is sleeping... Just stay put and let the algos run their course
- ·3 t sitten · MuokattuNo one can guarantee anything in listed stocks. What one knows is that Circio has made significant progress in its technology development with several results, they underpin each other and reveal the potential of circVec. A number of collaboration projects with external parties testing the technology, a paid study from big pharma, all help to substantiate that there is substance in the technology they have developed over the last 3 years. Large amounts have been invested. Furthermore, we now know that a financial basis for further developing circVec is guaranteed. The assessment is whether this justifies an mcap of 2 -250.mill including the capital that is now coming in. What is the risk compared to the possible reward in the next 12 months? My opinion is that it will take little in terms of new good results or agreements before one will see a completely different mcap for Circio. As a shareholder, one just has to live through these 14 emission days. Circio's emission cannot be compared with most others that one has seen in recent years. I do not want to be out of this stock for the next six months.·1 t sitten · MuokattuI'm not a bio expert, but after having been in and out of various such bio stocks in recent years, it is my personal opinion that this is the biotech stock on the exchange here that has the most potential and best risk/reward. The entry price and mcap are still low, the technology has enormous potential in many treatments and areas, the risk is lower as it will not primarily run its own long-term studies with win-or-lose outcomes. The risk is spread across many areas. And now the financing is finally in place.
- ·5 t sittenWhat are the odds that this becomes like zenith energy, falling down to 0.4/0.5 and going up and down a few percent there for a lifetime? Need some convincing words here soon😂
- ·5 t sittenWho thinks that circio can actually come with some news early next week to get as many as possible to buy shares and subscribe to the emission. 🧲
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
21 217
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 250 | - | - | ||
| 2 000 | - | - | ||
| 22 524 | - | - | ||
| 2 076 | - | - |
Ylin
1,07VWAP
Alin
0,987VaihtoMäärä
2,3 2 224 688
VWAP
Ylin
1,07Alin
0,987VaihtoMäärä
2,3 2 224 688
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
2025 Q2 -tulosraportti
141 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenNow, the lack of insider buying can no longer be used against Circio. More such announcements will come as the entire management/board invests in this emission. A clearer "message" is hard to find.
- ·1 t sitten · MuokattuExciting announcement!!·11 min sittenThe market is sleeping... Just stay put and let the algos run their course
- ·3 t sitten · MuokattuNo one can guarantee anything in listed stocks. What one knows is that Circio has made significant progress in its technology development with several results, they underpin each other and reveal the potential of circVec. A number of collaboration projects with external parties testing the technology, a paid study from big pharma, all help to substantiate that there is substance in the technology they have developed over the last 3 years. Large amounts have been invested. Furthermore, we now know that a financial basis for further developing circVec is guaranteed. The assessment is whether this justifies an mcap of 2 -250.mill including the capital that is now coming in. What is the risk compared to the possible reward in the next 12 months? My opinion is that it will take little in terms of new good results or agreements before one will see a completely different mcap for Circio. As a shareholder, one just has to live through these 14 emission days. Circio's emission cannot be compared with most others that one has seen in recent years. I do not want to be out of this stock for the next six months.·1 t sitten · MuokattuI'm not a bio expert, but after having been in and out of various such bio stocks in recent years, it is my personal opinion that this is the biotech stock on the exchange here that has the most potential and best risk/reward. The entry price and mcap are still low, the technology has enormous potential in many treatments and areas, the risk is lower as it will not primarily run its own long-term studies with win-or-lose outcomes. The risk is spread across many areas. And now the financing is finally in place.
- ·5 t sittenWhat are the odds that this becomes like zenith energy, falling down to 0.4/0.5 and going up and down a few percent there for a lifetime? Need some convincing words here soon😂
- ·5 t sittenWho thinks that circio can actually come with some news early next week to get as many as possible to buy shares and subscribe to the emission. 🧲
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
21 217
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 136 | - | - | ||
| 250 | - | - | ||
| 2 000 | - | - | ||
| 22 524 | - | - | ||
| 2 076 | - | - |
Ylin
1,07VWAP
Alin
0,987VaihtoMäärä
2,3 2 224 688
VWAP
Ylin
1,07Alin
0,987VaihtoMäärä
2,3 2 224 688
Välittäjätilasto
Dataa ei löytynyt